ZENITHDRUG Stock Overview
Operates as a pharmaceutical manufacturing and trading company in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Zenith Drugs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹83.35 |
| 52 Week High | ₹154.40 |
| 52 Week Low | ₹52.80 |
| Beta | 0 |
| 1 Month Change | -11.19% |
| 3 Month Change | -34.06% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.73% |
Recent News & Updates
Shareholder Returns
| ZENITHDRUG | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -6.3% | 0.8% | -4.2% |
| 1Y | n/a | 39.7% | 19.1% |
Return vs Industry: Insufficient data to determine how ZENITHDRUG performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ZENITHDRUG performed against the Indian Market.
Price Volatility
| ZENITHDRUG volatility | |
|---|---|
| ZENITHDRUG Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: ZENITHDRUG's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: ZENITHDRUG's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 61 | Sandeep Bhardwaj | zenithdrugs.com |
Zenith Drugs Limited operates as a pharmaceutical manufacturing and trading company in India and internationally. The company offers products in the areas of electrolytes, analgesic, antipyretic, NSAIDs, anti-inflammatory, antiemetic, cold, cough, antihistaminic and antiasthmatic, antibacterial, antifungal, anti-infective, antiparasitic, antiviral, anthelmintic, anti-scabies, antimicrobial, antimalarial, disinfectant, antiseptic, corticosteroids, depigmenting agents, gastrointestinal, liver, kidney, skin care, antibiotic preparations, nutrition supplements, and others. It also provides a range of formulations in various forms, such as ORS powder, liquid orals, ointments, creams, gels, tablets, liquid externals, and capsules.
Zenith Drugs Limited Fundamentals Summary
| ZENITHDRUG fundamental statistics | |
|---|---|
| Market cap | ₹1.43b |
| Earnings (TTM) | ₹95.93m |
| Revenue (TTM) | ₹1.32b |
14.9x
P/E Ratio1.1x
P/S RatioIs ZENITHDRUG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZENITHDRUG income statement (TTM) | |
|---|---|
| Revenue | ₹1.32b |
| Cost of Revenue | ₹855.07m |
| Gross Profit | ₹461.12m |
| Other Expenses | ₹365.20m |
| Earnings | ₹95.93m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.59 |
| Gross Margin | 35.03% |
| Net Profit Margin | 7.29% |
| Debt/Equity Ratio | 39.5% |
How did ZENITHDRUG perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield7%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 15:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zenith Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|